Sitaxsentan therapy for pulmonary arterial hypertension (Q34278168)

1 August 2017

Sitaxsentan therapy for pulmonary arterial hypertension (English)

1 reference

1 August 2017

1 reference

1

Robyn J Barst

1 reference

1 August 2017

David Langleben

2

1 reference

1 August 2017

Adaani Frost

3

1 reference

1 August 2017

Evelyn M Horn

4

1 reference

1 August 2017

Ronald Oudiz

5

1 reference

1 August 2017

Shelley Shapiro

6

1 reference

1 August 2017

Vallerie McLaughlin

7

1 reference

1 August 2017

Nicholas Hill

8

1 reference

1 August 2017

Victor F Tapson

9

1 reference

1 August 2017

Ivan M Robbins

10

1 reference

1 August 2017

Diane Zwicke

11

1 reference

1 August 2017

Benjamin Duncan

12

1 reference

1 August 2017

Richard A F Dixon

13

1 reference

1 August 2017

Lyn R Frumkin

14

1 reference

1 August 2017

STRIDE-1 Study Group

15

1 reference

1 August 2017

language of work or name

English

0 references

publication date

20 November 2003

1 reference

American Journal of Respiratory and Critical Care Medicine

1 August 2017

1 reference

1 August 2017

169

1 reference

1 August 2017

441-447

1 reference

1 August 2017

4

1 reference

Physiology and pharmacology of endothelins

1 August 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

21 January 2018

Endothelin antagonists

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

Treatment of primary pulmonary hypertension -- the next generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

A review of some statistical methods for covariance analysis of categorical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

New Tables for Multiple Comparisons with a Control

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200307-957OC

10.1164/RCCM.200307-957OC

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference